GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM) with a pKb of 7.26. The EC50 of GAT211 for cAMP and β-arrestin2 are 260 nM and 650 nM respectively. GAT211 may be utilized in study/research of neuropathic and/or inflammatory pain.

Physicochemical Properties

Molecular Formula	C22H18N2O2
Molecular Weight	342.4
Exact Mass	342.136
CAS #	102704-40-5
PubChem CID	4402318
Appearance	White to off-white solid powder
Density	1.2±0.1 g/cm3
Boiling Point	585.8±50.0 °C at 760 mmHg
Flash Point	308.1±30.1 °C
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.668
LogP	6.23
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Heavy Atom Count	26
Complexity	465
Defined Atom Stereocenter Count	0
InChi Key	OHZDCJJHWPHZJD-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H18N2O2/c25-24(26)15-19(16-9-3-1-4-10-16)21-18-13-7-8-14-20(18)23-22(21)17-11-5-2-6-12-17/h1-14,19,23H,15H2
Chemical Name	3-(2-nitro-1-phenylethyl)-2-phenyl-1H-indole
Synonyms	GAT-211; GAT 211; GAT211
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	GAT211 had a t1/2 of 8.67 minutes and 28.4 minutes, respectively, in both scaffold and human liver microsomes [2].
ln Vivo	GAT211 (0.3 mg/kg, 1 mg/kg, 3 mg/kg; 5 ml/kg; intraperitoneally; 2 doses 5 minutes apart) dose-like reductions in auditory startle reactions and locomotor activity. GAT211 was administered with a volume of 5 mL/kg after being dissolved in ethanol, kolliphor, and saline at a ratio of 1:1:6[3].
References	[1]. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem. 2021 Nov 15;50:116421. [2]. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology (Berl). [3]. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry. 2018 Nov 15;84(10):722-733.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~292.06 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.9206 mL	14.6028 mL	29.2056 mL
	5 mM	0.5841 mL	2.9206 mL	5.8411 mL
	10 mM	0.2921 mL	1.4603 mL	2.9206 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.